HVL Parent

Helsinn is a privately-held Swiss pharmaceutical group, operating under the parent entity HVL Parent SA, that focuses on oncology and cancer supportive care. The company's business model is centered on licensing and developing a diverse portfolio of targeted therapies and supportive care products to improve the lives of people with cancer. Its commercial portfolio includes Akynzeo and Aloxi for chemotherapy-induced nausea and vomiting, as well as Truseltiq for the treatment of cholangiocarcinoma. Helsinn maintains a fully integrated value chain with research and development, clinical development, and global commercialization capabilities. Additionally, the group operates specialized manufacturing facilities for high-potency active pharmaceutical ingredients and finished dosage forms in Switzerland and Ireland.